BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
BIT:1BMY - Euronext Milan - US1101221083 - Common Stock - Currency: EUR
Taking everything into account, 1BMY scores 5 out of 10 in our fundamental rating. 1BMY was compared to 50 industry peers in the Pharmaceuticals industry. 1BMY has only an average score on both its financial health and profitability. 1BMY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally 1BMY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year 1BMY was profitable.
In the past year 1BMY had a positive cash flow from operations.
In multiple years 1BMY reported negative net income over the last 5 years.
In the past 5 years 1BMY always reported a positive cash flow from operatings.
1.2 Ratios
1BMY has a Return On Assets (5.86%) which is in line with its industry peers.
The Return On Equity of 1BMY (31.16%) is better than 77.36% of its industry peers.
1BMY has a Return On Invested Capital of 14.13%. This is in the better half of the industry: 1BMY outperforms 77.36% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1BMY is below the industry average of 14.75%.
The last Return On Invested Capital (14.13%) for 1BMY is above the 3 year average (11.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROIC | 14.13% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
Looking at the Profit Margin, with a value of 11.38%, 1BMY is in line with its industry, outperforming 52.83% of the companies in the same industry.
1BMY's Operating Margin of 27.11% is fine compared to the rest of the industry. 1BMY outperforms 73.58% of its industry peers.
In the last couple of years the Operating Margin of 1BMY has declined.
The Gross Margin of 1BMY (74.69%) is better than 67.92% of its industry peers.
In the last couple of years the Gross Margin of 1BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1BMY is still creating some value.
The number of shares outstanding for 1BMY has been reduced compared to 1 year ago.
1BMY has less shares outstanding than it did 5 years ago.
1BMY has a worse debt/assets ratio than last year.
2.2 Solvency
1BMY has an Altman-Z score of 2.08. This is not the best score and indicates that 1BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
1BMY has a worse Altman-Z score (2.08) than 62.26% of its industry peers.
1BMY has a debt to FCF ratio of 3.80. This is a good value and a sign of high solvency as 1BMY would need 3.80 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.80, 1BMY is in line with its industry, outperforming 56.60% of the companies in the same industry.
1BMY has a Debt/Equity ratio of 2.67. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.67, 1BMY is doing worse than 79.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Altman-Z | 2.08 |
ROIC/WACC1.56
WACC9.08%
2.3 Liquidity
A Current Ratio of 1.28 indicates that 1BMY should not have too much problems paying its short term obligations.
The Current ratio of 1BMY (1.28) is worse than 60.38% of its industry peers.
A Quick Ratio of 1.17 indicates that 1BMY should not have too much problems paying its short term obligations.
1BMY has a Quick ratio of 1.17. This is in the better half of the industry: 1BMY outperforms 73.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1BMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 599.05%, which is quite impressive.
Measured over the past years, 1BMY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
The Revenue has been growing slightly by 4.62% in the past year.
Measured over the past years, 1BMY shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
3.2 Future
The Earnings Per Share is expected to grow by 37.10% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -4.93% on average over the next years.
EPS Next Y509.67%
EPS Next 2Y133.09%
EPS Next 3Y74.89%
EPS Next 5Y37.1%
Revenue Next Year-3.36%
Revenue Next 2Y-5.2%
Revenue Next 3Y-3.73%
Revenue Next 5Y-4.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.50, the valuation of 1BMY can be described as very cheap.
Based on the Price/Earnings ratio, 1BMY is valued cheaper than 92.45% of the companies in the same industry.
When comparing the Price/Earnings ratio of 1BMY to the average of the S&P500 Index (27.28), we can say 1BMY is valued rather cheaply.
With a Price/Forward Earnings ratio of 7.71, the valuation of 1BMY can be described as very cheap.
Based on the Price/Forward Earnings ratio, 1BMY is valued cheaply inside the industry as 94.34% of the companies are valued more expensively.
1BMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.5 | ||
| Fwd PE | 7.71 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1BMY is valued cheaply inside the industry as 86.79% of the companies are valued more expensively.
1BMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1BMY is cheaper than 94.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.43 | ||
| EV/EBITDA | 6.38 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMY's earnings are expected to grow with 74.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y133.09%
EPS Next 3Y74.89%
5. Dividend
5.1 Amount
1BMY has a Yearly Dividend Yield of 4.89%, which is a nice return.
Compared to an average industry Dividend Yield of 3.03, 1BMY pays a better dividend. On top of this 1BMY pays more dividend than 86.79% of the companies listed in the same industry.
1BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
5.2 History
On average, the dividend of 1BMY grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1BMY pays out 90.59% of its income as dividend. This is not a sustainable payout ratio.
The dividend of 1BMY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP90.59%
EPS Next 2Y133.09%
EPS Next 3Y74.89%
BIT:1BMY (5/27/2025, 7:00:00 PM)
41.495
+0.26 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.11%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap84.45B
Analysts67.5
Price Target49.08 (18.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.89% |
Yearly Dividend2.1
Dividend Growth(5Y)11.67%
DP90.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.45%
Min EPS beat(2)13.54%
Max EPS beat(2)19.36%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)13.54%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)11.3%
EPS beat(12)11
Avg EPS beat(12)9.38%
EPS beat(16)15
Avg EPS beat(16)7.79%
Revenue beat(2)2
Avg Revenue beat(2)4.66%
Min Revenue beat(2)3.68%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.59%
Min Revenue beat(4)3.68%
Max Revenue beat(4)5.63%
Revenue beat(8)6
Avg Revenue beat(8)1.95%
Revenue beat(12)8
Avg Revenue beat(12)1.4%
Revenue beat(16)10
Avg Revenue beat(16)1.19%
PT rev (1m)-11.93%
PT rev (3m)-12.22%
EPS NQ rev (1m)-2.94%
EPS NQ rev (3m)-4.8%
EPS NY rev (1m)0%
EPS NY rev (3m)1.94%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.5 | ||
| Fwd PE | 7.71 | ||
| P/S | 2.04 | ||
| P/FCF | 7.43 | ||
| P/OCF | 6.79 | ||
| P/B | 5.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.38 |
EPS(TTM)6.38
EY15.38%
EPS(NY)5.38
Fwd EY12.97%
FCF(TTM)5.59
FCFY13.46%
OCF(TTM)6.11
OCFY14.72%
SpS20.33
BVpS7.42
TBVpS-11.45
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROCE | 18.89% | ||
| ROIC | 14.13% | ||
| ROICexc | 17.06% | ||
| ROICexgc | 77.14% | ||
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% | ||
| FCFM | 27.47% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.7%
ROICexgc(3y)74.94%
ROICexgc(5y)75.96%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Debt/EBITDA | 2.21 | ||
| Cap/Depr | 15.15% | ||
| Cap/Sales | 2.57% | ||
| Interest Coverage | 6.1 | ||
| Cash Conversion | 68.16% | ||
| Profit Quality | 241.48% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.08 |
F-Score7
WACC9.08%
ROIC/WACC1.56
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
EPS Next Y509.67%
EPS Next 2Y133.09%
EPS Next 3Y74.89%
EPS Next 5Y37.1%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
Revenue Next Year-3.36%
Revenue Next 2Y-5.2%
Revenue Next 3Y-3.73%
Revenue Next 5Y-4.93%
EBIT growth 1Y22.52%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year282.44%
EBIT Next 3Y50.39%
EBIT Next 5Y24.24%
FCF growth 1Y18.09%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y17.06%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%